Low-dose aspirin use in the first trimester of pregnancy and odds of congenital anomalies : A meta-analysis of randomized controlled trials
© 2022 International Federation of Gynecology and Obstetrics..
BACKGROUND: Daily low-dose aspirin (LDA) is recommended in high-risk pregnancies. However, its safety profile in the first trimester has not been well documented.
OBJECTIVES: To determine if LDA exposure during the first trimester of pregnancy is associated with higher odds of congenital structural anomalies.
SEARCH STRATEGY: PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were systematically searched.
SELECTION CRITERIA: Randomized controlled trials (RCTs) that assigned participants to LDA (≤150 mg) or placebo/no intervention at less than 14 weeks of pregnancy were eligible.
DATA COLLECTION AND ANALYSIS: Random-effects models were performed using the inverse-variance method to calculate pooled effect sizes. Quality of evidence was appraised according to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria.
MAIN RESULTS: Eight RCTs that included 7564 participants assigned to receive daily LDA and 7670 participants that served as controls were analyzed. Low-certainty evidence showed no significant difference in the odds of congenital anomalies (odds ratio 0.87, 95% confidence interval 0.62-1.23, I2 = 0%).
CONCLUSIONS: In this meta-analysis, there is no evidence to suggest safety concerns regarding LDA teratogenicity. However, given the overall low quality of evidence, further research (e.g. individual participant data meta-analysis) is needed to confirm LDA safety profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics - 160(2023), 2 vom: 21. Feb., Seite 526-537 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garza-Galvan, Maria E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aspirin |
|---|
| Anmerkungen: |
Date Completed 19.01.2023 Date Revised 19.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijgo.14334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343308916 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343308916 | ||
| 003 | DE-627 | ||
| 005 | 20231226020137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijgo.14334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343308916 | ||
| 035 | |a (NLM)35810407 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garza-Galvan, Maria E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low-dose aspirin use in the first trimester of pregnancy and odds of congenital anomalies |b A meta-analysis of randomized controlled trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2023 | ||
| 500 | |a Date Revised 19.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 International Federation of Gynecology and Obstetrics. | ||
| 520 | |a BACKGROUND: Daily low-dose aspirin (LDA) is recommended in high-risk pregnancies. However, its safety profile in the first trimester has not been well documented | ||
| 520 | |a OBJECTIVES: To determine if LDA exposure during the first trimester of pregnancy is associated with higher odds of congenital structural anomalies | ||
| 520 | |a SEARCH STRATEGY: PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were systematically searched | ||
| 520 | |a SELECTION CRITERIA: Randomized controlled trials (RCTs) that assigned participants to LDA (≤150 mg) or placebo/no intervention at less than 14 weeks of pregnancy were eligible | ||
| 520 | |a DATA COLLECTION AND ANALYSIS: Random-effects models were performed using the inverse-variance method to calculate pooled effect sizes. Quality of evidence was appraised according to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria | ||
| 520 | |a MAIN RESULTS: Eight RCTs that included 7564 participants assigned to receive daily LDA and 7670 participants that served as controls were analyzed. Low-certainty evidence showed no significant difference in the odds of congenital anomalies (odds ratio 0.87, 95% confidence interval 0.62-1.23, I2 = 0%) | ||
| 520 | |a CONCLUSIONS: In this meta-analysis, there is no evidence to suggest safety concerns regarding LDA teratogenicity. However, given the overall low quality of evidence, further research (e.g. individual participant data meta-analysis) is needed to confirm LDA safety profile | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a aspirin | |
| 650 | 4 | |a congenital anomalies | |
| 650 | 4 | |a first trimester | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a randomized controlled trials | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Ferrigno, Ana S |e verfasserin |4 aut | |
| 700 | 1 | |a Campos-Zamora, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Bain, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Easter, Sarah Rae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jimin |e verfasserin |4 aut | |
| 700 | 1 | |a Figueras, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Farber, Michaela K |e verfasserin |4 aut | |
| 700 | 1 | |a Lumbreras-Marquez, Mario I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics |d 1973 |g 160(2023), 2 vom: 21. Feb., Seite 526-537 |w (DE-627)NLM000003336 |x 1879-3479 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2023 |g number:2 |g day:21 |g month:02 |g pages:526-537 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijgo.14334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2023 |e 2 |b 21 |c 02 |h 526-537 | ||